- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02237625
Natural History Study of Patients With Hypophosphatasia (HPP) (NatHisHPP)
Natural History Study of Adult and Pediatric Patients With Hypophosphatasia
Study Overview
Status
Conditions
Detailed Description
Inheritance can be autosomal recessive or dominant, and penetrance is variable resulting in a wide range of clinical expressivity, with a spectrum ranging from stillbirth without mineralized bone to early loss of teeth without bone symptoms. Depending on the age at diagnosis six clinical forms are currently recognized: perinatal (lethal), perinatal benign, infantile, childhood, adult and odontohypophosphatasia. Severe forms of HPP (perinatal and infantile) are inherited as an autosomal recessive trait and in milder forms (adult and odontohypophosphatasia) autosomal recessive and autosomal dominant inheritance coexist.
Because of the rarity of HPP as well as the side spectrum of both clinical presentation and inheritance patterns of the HPP trait, a natural history study cataloging specific clinical data with HPP would prove invaluable for future research into this disease. Specifically, it is our goal to create a comprehensive multi-discipline modality for care for hypophosphatasia patients, researching clinical manifestations of the disease such as extent of bone disease, ophthalmologic manifestations, orthopedic issues, renal issues, musculoskeletal manifestations as well as other more anecdotal findings such as those seen with cochlear implant failures and/or early menopause.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Janet G Blount, BA
- Phone Number: 919-681-7962
- Email: janet.blount@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Medical Center
-
Contact:
- Priya Kishnani, MD
- Phone Number: 919-681-1939
- Email: kishn001@mc.duke.edu
-
Contact:
- Stephanie DeArmey, PA-C
- Phone Number: (919) 681-1946
- Email: dearm001@mc.duke.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients or their legal representative must provide written informed consent or, if applicable, qualify for waiver of consent.
Patients must have a pre-established clinical diagnosis of HPP, as indicated by one or more of the following:
- Serum alkaline phosphatase (ALP) below the age-adjusted normal range
- Plasma PLP at least twice the upper limit of normal (no vitamin B6 administered for at least 1 week prior to determination)
- Evidence of osteopenia or osteomalacia on skeletal radiographs
- Genetic analysis fof the ALPL gene
- Must be current patient in the Duke University System.
Exclusion Criteria:
- Any patient without confirmation of clinical diagnosis of HPP.
Study Plan
How is the study designed?
Design Details
- Observational Models: Family-Based
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Medical History of HPP Patients
Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medical History of HPP Patients
Time Frame: 100 years
|
Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP
|
100 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
long-term efficacy of treatment modalities
Time Frame: 100 years
|
100 years
|
potential long term complications of the disease and/or treatment
Time Frame: 100 years
|
100 years
|
quality of life issues for patients living with hypophosphatasia
Time Frame: 100 years
|
100 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Priya Kishnani, MD, Duke University
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00049204 (Other Identifier: DUHS IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypophosphatasia
-
AlexionEnrolling by invitationHypophosphatasia (HPP)France, Poland, United Kingdom, Germany, Spain, Saudi Arabia, United States, Canada, Russian Federation, Australia, Italy
-
Hvidovre University HospitalOdense University HospitalActive, not recruitingHypophosphatasia (HPP)Denmark
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Taiwan, United Kingdom, Australia, Canada, Germany, Spain
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada, United Arab Emirates, United Kingdom
-
Alexion Pharmaceuticals, Inc.RecruitingHypophosphatasiaUnited States, Japan, Italy, Turkey, Australia, Germany, United Kingdom, Argentina, France, Canada, India
-
Alexion Pharmaceuticals, Inc.Not yet recruiting